Browse News

Found 1,894 articles

• CairnSurgical Announces First Patient Treated in Pivotal Clinical Trial of Breast Cancer Locator System

  1/21/2021

  CairnSurgical, Inc., an innovator striving to make breast cancer surgery more precise, announced today that the first patient has been treated in its U.S. pivotal trial of the Breast Cancer Locator (BCL) System at Massachusetts General Hospital.

• Caris Life Sciences Accurately Identifies 21 Cancer Types Using Artificial Intelligence Derived Molecular Signatures

  1/19/2021

  Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced positive results from a study using MI GPSai™ an artificial intelligence driven product using DNA sequencing and whole transcriptome data to aid in the diagnosis of cancer.

• Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference

  1/13/2021

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, presented at the J.P. Morgan 39th Annual Healthcare Conference (a virtual event) in the evening of January 13, Beijing Time

• Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadership

  1/11/2021

  -- AYVAKIT™ (avapritinib) granted FDA breakthrough therapy designation for the treatment of moderate to severe indolent systemic mastocytosis -- -- Positive top-line results from Phase 1 healthy volunteer trial of BLU-263 support plans to initiate Phase 2 HARBOR trial in non-advanced systemic mastocytosis in mid-2021 -- -- Nominated potential first-in-class development candidate targeting double-mutant EGFR, deepening leadership in lung cancer --

• Blueprint Medicines Announces R&D Leadership Transitions

  1/11/2021

  -- Becker Hewes, M.D., promoted to Chief Medical Officer -- -- Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice President, Clinical Development -- -- Marion Dorsch, Ph.D., Chief Scientific Officer, to depart the company

• Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy

  1/11/2021

  Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, and Blueprint Genetics, a Quest Diagnostics company, today announced the Resonate program.

• Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

  1/11/2021

  Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its pipeline of innovative vaccines with three new development programs based on the clinical success of its infectious disease vaccine portfolio to date.

• Agendia to Participate in the 39th Annual J.P. Morgan Healthcare Conference

  1/11/2021

  Agendia to Participate in the 39 th Annual J.P. Morgan Healthcare Conference

• Wellcome Sanger Institute Increases Investment in PacBio Long-Read Sequencing to Support Darwin Tree of Life Research Initiative

  1/8/2021

  Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Systems to increase its long-read sequencing capabilities for projects including the Darwin Tree of Life (DToL; all eukaryotes in Britain and Ireland) and Aquatic Symbiosis G

• Caris Life Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on January 12, 2021, at 12:10 p.m. ET.

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 05, 2021

  1/5/2021

  Blueprint Medicines Corporation announced that, effective on January 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 7,675 shares of its common stock and an aggregate of 3,837 restricted stock units to three new employees under Blueprint Medicines' 2020 Inducement Plan.

• CHOP Researchers Receive Funding to Study Effects of COVID-19 on Preterm Birth

  12/17/2020

  Independence Blue Cross Foundation and Highmark Delaware provide $300,000 to new consortium, which includes Nemours Children's Health, Yale University and Northwestern University, that will study the COVID-19 pandemic's effects on birth outcomes and prenatal care utilization

• Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis

  12/17/2020

  Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for AYVAKIT™

• INOVIO to Develop DNA-encoded Monoclonal Antibody (dMAb®) Candidates to Treat COVID-19 with Funding from the Defense Advanced Research Projects Agency (DARPA)

  12/15/2020

  - DARPA to fund innovative public-private partnership between INOVIO, The Wistar Institute, AstraZeneca, the University of Pennsylvania and Indiana University - $37.6 million grant from DARPA will leverage AstraZeneca's monoclonal antibody and INOVIO's DNA-encoded monoclonal antibody (dMAb®) technologies in the fight against COVID-19

• 

  Clinical Catch-Up: December 7-11

  12/14/2020

  It was an unusually busy week for clinical trial updates, largely because of the annual ASH meeting from Sunday December 5 through Wednesday December 9. There were also other meetings and the usual corporate updates.

• BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis

  12/14/2020

  BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the first patient has been dosed in the Phase 2 BLUEPRINT trial of BLU-5937,

• Artificial Intelligence Advances Showcased at the Virtual 2020 AACC Annual Scientific Meeting Could Help to Integrate This Technology Into Everyday Healthcare

  12/13/2020

  Artificial intelligence has the potential to revolutionize healthcare, but integrating AI-based techniques into routine medical practice has proven to be a significant challenge.

• Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint® for Clinical Low Risk Breast Cancer Patients at SABCS 2020

  12/11/2020

  Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted in an oral presentation by Laura van ’t Veer, Ph.D., Co-founder and Chief Research Officer, at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).

• Ginkgo Bioworks and Octant Partner to Expand COVID-19 Testing Capacity using Next-Generation Sequencing Technology

  12/10/2020

  Today, Ginkgo Bioworks , Inc. ("Ginkgo") and Octant, Inc ("Octant") announced a partnership to grow critical diagnostic testing capacity to address the COVID-19

• Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint® and BluePrint®

  12/10/2020

  Clinical utility of molecular subtyping and risk of recurrence profiling highlighted in largest-ever data set evaluating genomic testing in neoadjuvant setting